Valeant gets right to develop AstraZeneca's psoriasis drug

(Reuters) – Canada’s Valeant Pharmaceuticals International Inc said it has been granted an exclusive license by AstraZeneca Plc to develop and commercialize its late-stage experimental psoriasis drug brodalumab.



Source: ReuterBusiness

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *